Tatva Chintan Pharma Chem Authorizes KMPs for Materiality Disclosures
Tatva Chintan Pharma Chem Limited's Board authorized five Key Managerial Personnel (KMPs) to determine materiality of events for stock exchange disclosures as per SEBI regulations on 31 October 2025.
This is a procedural compliance announcement that clarifies which KMPs are responsible for determining materiality of events. It does not indicate any significant operational, financial, or strategic changes for the company, hence the low impact.
The announcement is a routine compliance update regarding the authorization of Key Managerial Personnel for disclosure purposes. It does not contain information that would directly impact the company's financial performance or business outlook positively or negatively.
Tatva Chintan Pharma Chem Limited's Board of Directors, at their meeting held on 31 October 2025, authorized the following Key Managerial Personnel (KMPs) to determine the materiality of events or information and for disclosure to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: * Mr. Chintan Nitinumar Shah, Managing Director * Mr. Ajay Mansukhlal Patel, Whole-time Director * Mr. Shekhar Rasiklal Somani, Whole-time Director * Mr. Ajesh Kumar Mohanan Pillai, Chief Financial Officer * Mr. Ishwar Nayi, Company Secretary and Compliance Officer This information will be made available on the company's website.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.